Xenon Pharmaceuticals Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Xenon Pharmaceuticals Inc. on September 27, 2016. The report discloses a corporate governance event regarding the appointment of a new director to the Board of Directors.
Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on personnel changes and does not contain financial statements or performance metrics.
Material Changes
The material change reported is the appointment of Dawn Svoronos as a director of the Company, effective September 27, 2016. This appointment was based on a recommendation from the nominating and corporate governance committee.
Guidance, Outlook, and Compensation
- Director Appointment: Ms. Svoronos was not appointed to any Board committees at the time of her initial appointment.
- Compensation: Ms. Svoronos will participate in the Company's standard compensation plan for non-employee directors. This includes an initial stock option grant awarded on September 27, 2016.
- Policy Reference: The compensation plan details are described in the "Director Compensation Policy for Fiscal Year 2015" section of the Company's definitive proxy statement on Schedule 14A, filed on April 27, 2016.
- Related Party Transactions: There are no transactions or proposed transactions between Ms. Svoronos (or her immediate family) and the Company, nor any arrangements regarding her appointment.
Key Facts for Investor Verification
- Verify the terms of the initial stock option grant awarded to Dawn Svoronos on September 27, 2016.
- Review the "Director Compensation Policy for Fiscal Year 2015" in the Schedule 14A proxy statement filed on April 27, 2016, to understand the full scope of non-employee director compensation.
- Confirm the press release attached as Exhibit 99.1 for additional context on the appointment.